spec sheet11 rows
Modafiendz is a fluorinated, N-methylated analog of the wakefulness agent modafinil, marketed online as a next-generation nootropic alternative. It is built around the same eugeroic blueprint that made modafinil a favorite for focus and sustained alertness, with structural tweaks intended to modify its activity. Because the analog itself has not been formally studied, it is best understood as an experimental research chemical riding on the well-mapped pharmacology of its parent.
- Next generation take on the modafinil blueprint
- Wakefulness that pushes fatigue out of the way
- Built for long, deep focus sessions
- Smoother and less jittery than classic stimulants
- Low abuse potential across related analogs
- Oral, simple, no fuss
- Headache or anxiety, common to eugeroics
- Insomnia if taken too late in the day
- Possible elevated heart rate or blood pressure
Overview
Modafiendz is a designer analog of modafinil, identified in the chemical literature as N-methyl-4,4-difluoro-modafinil, a version of the parent molecule that carries two fluorine atoms on its benzhydryl rings and an added methyl group [1]. It emerged in the online nootropic market as one of several modafinil alternatives sold alongside adrafinil and the fluorinated compounds CRL-40,940 and CRL-40,941, marketed to buyers seeking the focus and wakefulness associated with modafinil [1].
The honest starting point is that Modafiendz itself has essentially no dedicated pharmacological research. The one peer-reviewed study that names it did so in a forensic and analytical context, examining how the compound behaves during laboratory testing rather than measuring any effect in humans or animals [1]. As a result its potency, duration, safety, and even the consistency of what is sold under the name are not established, and it carries no regulatory approval of any kind.
What is well characterized is the parent drug it is derived from. Modafinil is an FDA-approved eugeroic, or wakefulness-promoting agent, used for narcolepsy, obstructive sleep apnea, and shift-work sleep disorder, and it is widely used off-label as a cognitive enhancer [4]. Its effects trace primarily to selective inhibition of the dopamine transporter, which raises extracellular dopamine, together with downstream changes in noradrenergic, orexin, histamine, and glutamate signaling [2][3]. The structural fluorination and methylation that define Modafiendz are the kind of medicinal-chemistry modifications typically intended to alter metabolism or potency, though in this case the practical consequences remain unmeasured.
In regulatory terms, Modafiendz is not an approved medicine and is handled purely as a research chemical, typically sold as a powder or capsule, with the usual cautions about unverified identity and purity [1].
- Modafiendz is a chemically tweaked cousin of modafinil, carrying added fluorine atoms and a methyl group intended to alter the parent drug's activity.
- No published studies have ever tested Modafiendz directly; its expected effects are inferred entirely from modafinil, one of the most thoroughly researched wakefulness agents.
Mechanism
Any mechanistic account of Modafiendz has to lean on its parent compound, because the analog itself has not been pharmacologically tested; the reasonable assumption is that a fluorinated, N-methylated modafinil retains the core wakefulness-promoting activity of modafinil while the structural changes may shift its metabolism or potency [1]. With that caveat, the biology of modafinil is well studied and provides the working model.
Modafinil is a eugeroic whose primary molecular action is selective inhibition of the (). Electrophysiological and amperometric experiments show that it binds the transporter at the same site as cocaine, blocking reuptake and raising extracellular dopamine, which is sufficient to explain most of its behavioral activation and its wake-promoting effect [2]. Unlike classical stimulants, it produces this effect without a strong release of , giving a smoother profile. Studies in genetically modified mice further indicate a dual mechanism in which both dopamine and contribute, with the need for norepinephrine bypassed when dopamine signaling is amplified [3].
Downstream of these catecholamine effects, modafinil indirectly raises cortical levels of , , , and while lowering , and activity in orexin-containing hypothalamic neurons is thought to help sustain the stable, long-lasting arousal characteristic of the drug [4][5]. The functional benefits reported for modafinil in healthy, non-sleep-deprived people are real but selective: a systematic review found consistent gains in executive function and, with more complex tasks, in attention and learning, without prominent mood changes, although simpler test batteries produced more mixed results [4]. Whether Modafiendz reproduces this profile, more strongly or more weakly, is unknown, since no comparable data exist for the analog [1][4].
receptor fingerprint
()Weakly inhibits reuptake, raising extracellular dopamine
Mesencephalic neuronsEngages the same arousal system modafinil relies on
and wake-promoting circuitsIndirectly activates arousal pathways
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Modafiendz is an unapproved research chemical with no quality control and essentially no long-term human safety data, so caution is the honest baseline. Expect the modafinil-style side effects, headache, anxiety, insomnia if taken late, and possibly a bumped heart rate or blood pressure. Because purity and actual content vary between vendors, you cannot really trust the dose in front of you. Given that modafinil itself can rarely cause serious rashes and reduce birth-control effectiveness, it is reasonable to assume this close analog carries similar risks. It is best treated as experimental, not a proven nootropic.
History
Modafiendz is a designer analog of the wakefulness-promoting drug modafinil, structurally a fluorinated, N-methylated version of the parent molecule; it appeared on the online research-chemical market as a nootropic alternative rather than through any pharmaceutical development program. Its history is therefore very short and largely undocumented: no published pharmacological or clinical studies of Modafiendz itself could be identified, and it has no regulatory approval anywhere.
Its rationale borrows entirely from modafinil, which was developed in France by Lafon Laboratories in the 1970s and 1980s from the earlier compound adrafinil, and which went on to become a widely prescribed eugeroic for narcolepsy and shift-work sleep disorder. Modafiendz is best understood as a structural spin-off created to sit outside existing regulatory schedules while aiming to reproduce modafinil's effects. Its potency, metabolism, and safety in humans remain uncharacterized.
Reputation
Modafiendz has a niche reputation within nootropic and research-chemical communities as a next-generation take on modafinil, prized in principle for the same qualities that made its parent famous: clean, sustained wakefulness and improved focus without the jittery edge of classical stimulants. That appeal is real, but it is essential to be candid that it rides almost entirely on modafinil's well-mapped pharmacology rather than on any data for the analog itself. Modafinil has a genuinely strong record, with systematic reviews reporting consistent gains in executive function in healthy users, which is the profile Modafiendz aspires to. For the analog specifically, however, no formal studies exist, so claims about its potency and safety are extrapolations. It is fairly described as an experimental compound with an intriguing pedigree but an unproven identity of its own.
Subjective profileweighing the evidence above
The reputation is borrowed, not earned; the analog itself has never been studied, so everything claimed for it is really a claim about modafinil. Add unverified identity and purity from research-chemical vendors and there is no good reason to choose it over modafinil itself.
Where to buy
Suppliers
Vendors carrying Modafiendz, with live product details and codes. Links are affiliate links that support the wiki at no cost to you.
Kimera Chems
Modafiendz
Research
- 2003first citedRole of executive function in ADHD.
- 2017most active year4 papers
- 2024most recentThe Structural Basis of the Activity Cliff in Modafinil-Based Dopamine Transporter Inhibitors.
- 1.Outsmarted by nootropics? An investigation into the thermal degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-40,941 in the GC injector: formation of 1,1,2,2-tetraphenylethane and its tetra fluoro analog.
- 2.Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation.
- 3.Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action.
- 4.Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review.
- 5.Role of executive function in ADHD.
- 6.Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.
- 7.Effects of ( R)-Modafinil and Modafinil Analogues on Dopamine Dynamics Assessed by Voltammetry and Microdialysis in the Mouse Nucleus Accumbens Shell.
- 8.Distinct effects of (R)-modafinil and its (R)- and (S)-fluoro-analogs on mesolimbic extracellular dopamine assessed by voltammetry and microdialysis in rats.
- 9.Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors.
- 10.Heterocyclic Analogues of Modafinil as Novel, Atypical Dopamine Transporter Inhibitors.
- 11.Structure-Activity Relationships of Novel Thiazole-Based Modafinil Analogues Acting at Monoamine Transporters.
- 12.Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues.
23 listed here; entry last updated August 2026
Reviews
- solid FLmoda analog
this is super damn stimulating, it's legit FLmoda but better. doesn't impact sleep for me, and is pretty nice works with flecainide and tropisetron. amazing combo choose a stim + flec or tropi, most usually tropi due to how cheap it is lol
0
My notesprivate to this device
FAQ
Is Modafiendz stronger than modafinil?
Marketers claim the fluorine tweaks make it more potent, but there is no solid human data to confirm that; the claim rests on chemistry and animal analogy, not trials.
Is it legal?
It is unapproved and sold as a research chemical; legal status varies by country and it is not a licensed medicine anywhere.
Will it wreck my sleep?
It can. Eugeroics in this family tend to have long tails, so taking it in the afternoon or evening often means a rough night.
Limitations of the evidence
- Unknown long-term safety; unverified identity and purity as a research chemical
Adverse effects
- Headache or anxiety, common to eugeroics
- Insomnia if taken too late in the day
- Possible elevated heart rate or blood pressure